Clinical trials: Endocrine Disorder
Ovarian Cancer
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer.
- Trial name
- CORAIL (NCT02421588)
- Testing
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Where
- 28 sites in United States
- Volunteers
- 442 people
- Sponsor
- PharmaMar
Type 1 Diabetes
Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH
To determine whether using a long-acting insulin analog at the time of diagnosis, instead of intermediate-acting insulin, affects the rate of loss of the body's ability to make insulin in children with newly diagnosed type 1…
- Trial name
- NCT00564018
- Testing
- Insulin detemir, Glargine, NPH
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Precocious Puberty
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
The purpose of the study is to assess the efficacy of triptorelin 11.25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years.
- Trial name
- DECAPUB (NCT00564850)
- Testing
- Triptorelin pamoate 11.25mg (Decapeptyl® SR)
- Where
- 18 sites in France
- Volunteers
- 37 people
- Sponsor
- Ipsen
Type 2 Diabetes Mellitus
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes…
- Trial name
- NCT01181674
- Testing
- insulin glargine, metformin, acarbose
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- Population Health Research Institute
Hydrocele, Inguinal Hernia
Study of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair Surgery
Study measures the difference in pain after hernia \&/or hydrocele repair based on site of local anesthesia injection.
- Trial name
- TAP (NCT01698268)
- Testing
- TAP block, Local Infiltration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Kaveh Aslani, MD
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes.
- Trial name
- SUSTAIN 11 (NCT03689374)
- Testing
- Semaglutide, Insulin aspart, Insulin glargine U100
- Where
- 210 sites in Bosnia and Herzegovina, Bulgaria and 19 more
- Volunteers
- 2,274 people
- Sponsor
- Novo Nordisk A/S
Peritoneal Surface Malignancy, Postoperative Adhesion
SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
This dual-centre, randomized controlled trial evaluates the safety and efficacy of high-purity Type-I collagen-based biomaterial, as a peritoneal substitute following peritonectomy in patients undergoing cytoreductive surgery…
- Conditions
- Peritoneal Surface Malignancy, Postoperative Adhesion, Bowel Obstruction, Wound Complications
- Trial name
- NCT07241091
- Testing
- High-Purity Type-I Collagen Scaffold, Standard Peritonectomy Closure
- Where
- 2 sites in India
- Volunteers
- 60 people
- Sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
Healthy, Type 2 Diabetes
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating.
- Trial name
- NCT04466618
- Testing
- Saline, Exendin-9,39, Saline + Intralipid/Heparin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Type 1 Diabetes
Incretin Effect and Use After Clinical Islet Transplantation
We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1…
- Trial name
- NCT00768651
- Testing
- Pantoprazole, Sitagliptin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Diabetes Mellitus, Type 2
Evaluation of a Computer-Based, Self-Management Tool for People With Type 2 Diabetes
NEW Brief Summary: Managing diet and physical activity are vital aspects of diabetes self-care; however, people with diabetes often find it difficult to make changes to their usual diet and physical activity patterns.
- Trial name
- LWD (NCT00877851)
- Testing
- Computer-based Program
- Where
- 2 sites in United Kingdom
- Volunteers
- 84 people
- Sponsor
- Queen's University, Belfast
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Pancreatic Cancer
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane.
- Trial name
- 278 (NCT01744353)
- Testing
- Dose level 1, Dose level 2/MTD, Dose level 3
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Brown University
Extrahepatic Bile Duct Cancer, Nausea
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer
- Trial name
- NCT01534637
- Testing
- aprepitant, gemcitabine hydrochloride, capecitabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM).
- Trial name
- NCT01640873
- Testing
- MK-8655
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control…
- Trial name
- NCT02409329
- Testing
- REACH, Helpline and A1c results, REACH + FAMS
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Vanderbilt University Medical Center
Metastatic Pancreatic Adenocarcinoma
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
This study will enroll patients who have metastatic pancreatic cancer and have progressed on prior chemotherapy. Part 1 (dose escalation) participants will receive epacadostat/pembrolizumab/cyclophosphamide(CY)/GVAX pancreas…
- Trial name
- NCT03006302
- Testing
- Epacadostat, Pembrolizumab, CRS-207
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Managing Diabetes to Gain Opportunities for a More Active Life
The purpose of this novel patient-facing disease management intervention is to develop and test a system embedded within the electronic medical record to engage patients in personalized goal setting and chronic disease management.
- Trial name
- NCT03692208
- Testing
- My Diabetes Goal Survey and Optional Care Management
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.